We’re wearing stripes to stand with patients facing rare cancers. Making progress for patients with minimal or no approved treatment options, including rare cancers like ACC and AML is why Remix was founded. Learn more: bit.ly/485hLGm #RareDiseaseDay #ShowYourStripes

Remix’s Co-Founder and CEO was recently featured in Pharmaceutical Technology, highlighting how modulating RNA processing can dramatically expand the universe of druggable targets. Read the article by Jam Bensilum here: bit.ly/4aKtGdL #REM422 #RNAdegradation #RNAdegraders #RNAtherapeutics

We’re looking forward to sharing how Remix is advancing a pipeline of innovative therapeutics in Oncology, uniquely designed to control RNA processing pathways and address disease drivers at their source at the Leerink Partners Global Healthcare Conference. #LeerinkGlobalHealthcare

Welcome Chip Michaud, Vice President of Finance, & Hayley Amemiya, Senior Scientist, Bioinformatics & Data Science, to Remix! Their leadership and experience will help us advance our next stage of growth addressing the intractable drivers of disease. #RemixTherapeutics

Amy Siu, MS, Remix’s Head of DMPK will be presenting at the upcoming SLAS 2026 Conference and Exhibition! Amy will be highlighting the role of physiologically based pharmacokinetic modeling in discovery and early nonclinical development. Learn more: bit.ly/4qkuTyj

Today, on World Cancer Day, we join the community #UnitedByUnique because behind every diagnosis is a deeply personal story. Through our work in Adenoid Cystic Carcinoma and AML, we hope to make meaningful progress on behalf of patients and their families. #WorldCancerDay

Kicking off our team fundraiser in support of the SCN8A Research Fund, to help make a real impact for patients affected by SCN8A-related epilepsy and neurodevelopmental disorders. Learn more: bit.ly/4k7FFq7 #RareDiseaseResearch#RemixTherapeutics #Community

Our Women’s Networking Group Book Club met to discuss The Elements of Marie Curie, focusing on her deep commitment to mentoring & encouraging women to pursue careers in science, reinforcing our commitment to developing the next generation of scientists at every stage.

Today, we announced the appointment of Mythili Koneru, MD, PhD, as our Chief Medical Officer, leading clinical development, medical strategy, and regulatory engagement. #mRNA #RNAdegradation #RNAdegraders #RNAtherapeutics #OncologyResearch #RemixTherapeutics Read the PR here: bit.ly/4qJply4

The Remix Therapeutics team will be at the JP Morgan 2026 Healthcare Conference January 12-15. Reach out to schedule a meeting: [email protected] See you in San Francisco! #JPM2026

ACC is a cancer of salivary glands, typically originating in the head and neck region. A growing body of research, including our work with REM-422, highlights the importance of addressing MYB, a previously intractable driver, in diseases like ACC. More here: bit.ly/4oXyim2

Remix will be attending the upcoming virtual RBC Capital Markets Healthcare Private Company Conference. Our CEO, Pete Smith, will be presenting on Dec 11th at 1:20 PM and will be joined by, CBO, Heather Wasserman, for investor meetings. #RBCHealthcare #RemixTherapeutics

Join us in supporting local organizations making a difference in our community, like MGH Caring for a Cure, offering support for patients & advancing life-saving research, & Rosie’s Place, providing safety & hope for women experiencing homelessness for 50+ years.

Our CSO, Dom Reynolds, PhD, will be highlighting the development of REM-422 for ACC, AML, and high-risk MDS and how our REMaster™ platform is advancing RNA-targeted drug discovery at the 8th RNA-Targeted Drug Discovery & Development Summit. #REM422 #mRNA #RemixTherapeutics

Our CEO, Pete Smith, PhD, will be attending the London Growth Summit, hosted by LifeSci Capital and Sofinnova Partners. Pete Smith, PhD, CEO, and Heather Wasserman, CBO, will be attending Jefferies Global Healthcare Conference. #JefferiesHealthcare #RemixTherapeutics

Our Co-Founder and CEO, Pete Smith, will present a corporate overview at the Guggenheim Second Annual Healthcare Innovation Conference on November 10 at 2:15 PM ET. The Remix management team will also be hosting one-on-one meetings with investors. ➡️https://bit.ly/4qEuRml

Our Co-Founder and CEO, Pete Smith, and Chief Business Officer, Heather Wasserman, will be participating in the Wells Fargo Virtual Private Biopharma Symposium on November 5. If you would like to schedule a meeting, please reach out to: [email protected]. #RemixTherapeutics

Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25 bit.ly/4ozZes8

Next week at the 8th Annual TPD & Induced Proximity Summit in Boston, our Chief Scientific Officer, Dom Reynolds, PhD, will be chairing a panel on “Next Gen Novel Molecular Glue Discovery” and presenting on “Strategies to Drug RNA-Protein Complexes with Small Molecules.”

Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25 ➡️ bit.ly/48u70iy

Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics Learn more: bit.ly/3VVRuo8

Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches. ➡️ More here: bit.ly/3VGrT2o

📣 Remix Chief Scientific Officer, Dominic Reynolds, PhD, will be speaking at the Small Molecules Targeting RNA & DNA Conference during the Discovery on Target event in Boston Sept 23-24. #RNAtherapeutics #RNAdegraders #RNAdegradation #mRNA #OncologyResearch

Hear from Remix’s Maria Alexis, Principal Scientist, Computational Biology, about the team’s published work on poison exons & how deeper insights into RNA biology are shaping the future of medicine. ➡️http://bit.ly/4pcj0v5

#BloodCancerAwarenessMonth is an important time to support patients and accelerate progress. Our lead program, REM-422, is in development for AML, which is one of the hardest-to-treat blood cancers with limited, effective treatment options.

Our team’s work to enable the discovery of small molecule modulators of mRNA processing to quantify transcript levels of multiple independent target genes within a single HTS campaign was published this week in ASSAY and Drug Development Technologies. Read more: bit.ly/45QKz4a

Today, we were honored to host cancer survivor and advocate Coney Flowers at Remix as we gear up for the #LightTheNight walk with The Leukemia & Lymphoma Society. Her story inspired hope and strengthened our commitment to new treatments for patients with blood disorders. Thank you, Coney!

Excellent discussion at the Canaccord Genuity 45th Annual Growth Conf, including our innovative REMaster discovery platform, the importance of targeting MYB as a driver of disease, the advancing clinical trials of REM-422 in ACC and AML, and our broader pipeline and partnerships.

Remix CEO and Co-Founder, Pete Smith will be taking part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston next week. #RemixTherapeutics

MYB is an oncogenic transcription factor that is dysregulated in cancers like ACC, AML, and HR-MDS. Our lead program, REM-422, is an oral mRNA degrader that reduces MYB mRNA and protein expression, resulting in antitumor activity in MYB-dependent human tumor models. ➡️http://bit.ly/4kJkYQ4

📣Next week, Co-Founder & CEO, Pete Smith, will be presenting on an Oncology panel and part of a Q&A session at Evercore's Emerging Private Biotech Conference. Looking forward to discussing Remix’s approach to tackling diseases by modulating RNA processing with small molecules. #Evercore #REM422

🌈 Proud to welcome OUTbio Founder Ramsey Johnson for a powerful session on OUTbio’s mission to empower LGBTQ professionals and allies across the industry. At Remix, we’re committed to fostering a culture of inclusion, authenticity, and belonging—within our walls and across biotech. Thank you!

Data presented in poster sessions at the @theaacr.bsky.social and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML. Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D

See you at BIO International next week! Heather Wasserman, Remix's CBO/COO will be onsite and looking forward to meeting with current partners and networking with new colleagues about Remix's innovative approach to addressing the intractable drivers of disease. #OncologyResearch #BIO2025

Sarah Sirin, Director & Head of Computational Chemistry, participated in Scientific Computing World’s roundtable on the data impact of working with emerging modalities, like RNA therapeutics and protein degraders. Learn more: bit.ly/3ZmPmbg

Learn more about Remix’s innovative approach to drug design. Head of Medicinal Chemistry, Benoit Moreau, will be speaking at the 2nd Structure Based Drug Design Summit Meeting & the Precision in Drug Discovery & Preclinical Summit: bit.ly/42KveRd bit.ly/3Y9k1YT

Closing out #mentalhealthmonth, we reflect on how we create a healthier, more human workplace at Remix - staying grounded and connected as a team by focusing on our mission while recharging with things like yoga, volunteering on the Charles, and showing up in green to support the cause.

This week, we hosted students from EVkids, a nonprofit that supports Boston youth, for a hands-on intro to biotech at Remix! From extracting a strawberry's DNA to learning how AI powers drug discovery, they explored the many career paths science has to offer. Grateful to be part of their journey!👨‍🔬🧬

Hear from Dom Reynolds, our Chief Scientific Officer, about his perspective on how Remix is tackling one of the biggest factors in being able to treat cancer and other difficult to treat diseases - undruggable proteins. bit.ly/3H5dsAX #OncologyResearch #ACC #AdenoidCysticCarcinoma #AML

Preclinical data evaluating anti-tumor activity of our lead program REM-422, a first-in-class degrader of the MYB oncogene, in xenograft models of AML has been selected for a poster presentation at the European Hematology Association 2025 Congress next month. bit.ly/4mhxTuD #EHA2025

📣Our CSO, Dom Reynolds, will be speaking tomorrow at the 5th Workshop on Splicing Factor Mutations and RNA Biology in Cancer, bringing together leaders in the research community for collaborative discussions to advance the field and new pathways for treatments. #OncologyResearch

📣 Benoit Moreau, Remix’s Head of Medicinal Chemistry, will be the Roundtable facilitator for the “From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins” session. ➡https://bit.ly/3RroSRu

CEO Pete Smith had an opportunity to participate in the “Drugging the Undruggable/Transcription Factors” panel at #AACR25. We're proud of Remix’s contributions in this field & hope to continue the conversation. Thank you Jonathan Chang/Leerink, the panelists & MPM BioImpact for a great discussion!

Charles Kung, PhD, presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. bit.ly/4c4FkAr

We teamed up with Jim Ellis' Brix & Merlot for our annual Wine Trivia fundraiser—raising a glass (and funds!) for a cause near and dear to a #Remixer. With sips and science on our minds, we put our brains to the test, in the name of fun, philanthropy, and #RemixingTogether. 🧠🍷

Today, on World Acute Myeloid Leukemia(AML) day, we are reflecting on the progress that has been made & the continued importance of research for effective treatment options. Our clinical trial REM-422 in patients with AML or Higher Risk MDS is ongoing. 👉https://bit.ly/4jfuhH9 #KnowAML

The Remix Women’s Group recently discussed The Immortal Life of Henrietta Lacks, a powerful story about medical ethics, legacy, and the woman behind the HeLa cells. Big thank you to Christoph Lengauer, CSO at Curie.Bio, for sharing his personal experiences from the story and the impact it had.

Today we announced the appointment of Linda C. Bain to our Board of Directors. Ms. Bain, who brings more than 20 years of financial, operational and executive leadership launching and growing innovative life sciences companies, is a Venture Partner at @atlasventure.bsky.social. bit.ly/4lvZFTN

Our CEO and Co-Founder, Pete Smith, will be joining a panel hosted by Rami Rahal, MPM BioImpact, to discuss the exciting progress we are making in “Drugging the Undruggable/Transcription Factors” at the American Society for Cancer Research Annual Meeting. See you there! #AACR25 #OncologyResearch

Our Co-Founder and CEO, @pgsmith.bsky.social, will be presenting a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET. Read the press release here: bit.ly/3FJGCos